Core Insights - Shanghai Junshi Biosciences Co., Ltd. announced that its self-developed PD-1 inhibitor, Hanshu (sulunlimab), achieved predefined efficacy standards in a Phase III clinical study for perioperative treatment of gastric cancer, marking a significant breakthrough in the field [1] - The company plans to expedite the application for market approval for this indication, emphasizing its commitment to transforming research results into patient benefits [1] - Gastric cancer poses a major public health challenge globally, with approximately 969,000 new cases and 660,000 deaths reported in 2022, ranking fifth in incidence and mortality among all cancers [2] Company Focus - The company is strategically focused on gastrointestinal tumors, with recent approvals and ongoing clinical studies in various cancer types, including esophageal squamous cell carcinoma and HER2-positive advanced gastric cancer [2] - The company is advancing multiple clinical trials, including a Phase III study for Hanshu in metastatic colorectal cancer and exploring new therapies such as PD-L1 antibody-drug conjugate HLX43 for advanced gastric and gastroesophageal junction adenocarcinoma [2][3] Future Plans - The company aims to leverage its innovative therapy matrix and extensive global clinical trial data to maintain its leading position in the gastrointestinal oncology field, with a commitment to delivering high-quality treatment options to a broader patient population [3]
胃癌术后不用再化疗？复宏汉霖汉斯状临床试验成功 为全球首个